Caleres, Inc. (NYSE:CAL) Short Interest Update

Caleres, Inc. (NYSE:CAL) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 4,620,000 shares, a growth of 17.6% from the February 13th total of 3,930,000 shares. Currently, 14.3% of the company’s stock are sold short. Based on an average trading volume of 814,700 shares, the short-interest ratio is presently 5.7 days.

Analyst Upgrades and Downgrades

Separately, Loop Capital decreased their price target on Caleres from $30.00 to $25.00 and set a “hold” rating for the company in a report on Friday, December 6th.

Insider Buying and Selling

In related news, Director Kyle Gendreau acquired 5,000 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was purchased at an average cost of $19.93 per share, with a total value of $99,650.00. Following the acquisition, the director now owns 5,000 shares of the company’s stock, valued at approximately $99,650. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CAL. Victory Capital Management Inc. lifted its position in shares of Caleres by 23.6% during the third quarter. Victory Capital Management Inc. now owns 76,577 shares of the textile maker’s stock worth $2,531,000 after acquiring an additional 14,618 shares in the last quarter. Quest Partners LLC lifted its holdings in Caleres by 6.6% during the 3rd quarter. Quest Partners LLC now owns 14,028 shares of the textile maker’s stock worth $464,000 after purchasing an additional 869 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Caleres during the 3rd quarter worth about $472,000. Landscape Capital Management L.L.C. bought a new position in Caleres in the 3rd quarter worth about $4,184,000. Finally, Pacer Advisors Inc. purchased a new position in Caleres during the 3rd quarter valued at about $49,783,000. 98.44% of the stock is owned by institutional investors.

Caleres Stock Performance

Caleres stock opened at $16.92 on Friday. The stock has a market cap of $568.83 million, a PE ratio of 3.77 and a beta of 1.82. Caleres has a fifty-two week low of $15.00 and a fifty-two week high of $44.51. The firm’s 50-day simple moving average is $17.68 and its 200 day simple moving average is $25.72.

Caleres (NYSE:CAL) last announced its earnings results on Thursday, March 20th. The textile maker reported $0.33 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.06. The firm had revenue of $639.20 million for the quarter, compared to the consensus estimate of $645.79 million. Caleres had a return on equity of 22.71% and a net margin of 5.69%. The company’s revenue was down 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.86 EPS. As a group, analysts predict that Caleres will post 3.23 EPS for the current fiscal year.

Caleres Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 11th. Stockholders of record on Thursday, March 27th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 1.66%. The ex-dividend date is Thursday, March 27th. Caleres’s payout ratio is 6.24%.

Caleres Company Profile

Caleres, Inc engages in the retail and wholesale of footwear business in the United States, Canada, East Asia, and internationally. It operates through Famous Footwear and Brand Portfolio segments. The company offers licensed, branded, and private-label athletic, casual, and dress footwear products. The company provides brand name athletic, casual, and dress shoes, including Nike, Skechers, adidas, Vans, Crocs, Converse, Puma, Birkenstock, New Balance, Under Armour, Dr.